Concentrations of selected monohydroxy polycyclic aromatic hydrocarbons across various stages of glomerular function.

The objective of this study was to evaluate the variabilities in the concentrations of selected monohydroxy polycyclic aromatic hydrocarbons (OH-PAH) in urine across various stages of glomerular function. Data from National Health and Nutrition Examination Survey for US adult smokers (N = 3125) and nonsmokers (N = 6793) were selected for analysis to meet the objectives of the study. OH-PAHs selected for analysis were as follows: 1-hydroxynaphthalene, 2-hydroxynaphthalene, 2-hydroxyfluorene, 3-hydroxyfluorene, 9-hydroxyfluorene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenanthrene, and 1-hydroxypyrene. Stages of glomerular function (GF) considered were as follows: hyperfiltrators (GF-1A, eGFR ≥ 110 mL/min/1.73 m2), normal filtrators (GF-1B, 90 < eGFR < 110 mL/min/1.73 m2), GF-2 (60 ≤ eGFR < 90 mL/min/1.73 m2), GF-3A (45 ≤ eGFR < 60 mL/min/1.73 m2), and GF-3B/4 (15 ≤ eGFR < 45 mL/min/1.73 m2). For the analysis of data for smokers, however, data for GF-3A and GF-3B/4 were merged because of small sample sizes for these GF stages for smokers. Among nonsmokers, (i) there was almost a straight-line decrease in adjusted concentrations of 2-hydroxyfluorene, 3-hydroxyfluorene, 9-hydroxyfluorene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenanthrene, and 1-hydroxypyrene over GF-1A through GF-3B/4; (ii) concentrations of these OH-PAHs at GF-3B/4 varied from being 37.5% for 1-hydroxypyrene to being 87% for 9-hydroxyfluorene of what they were at GF-1A; and (iii) while concentrations of 1-hydroxynaphthalene were located on an inverted U-shaped curve, concentrations of 2-hydroxynaphthalene were located on a U-shaped curve with pints of inflections at GF-3A. Among smokers, concentrations of all nine OH-PAHs in urine were located on inverted U-shaped curves with points of inflections located at GF-2 and concentrations of these OH-PAHs at GF-3/4 varied from being 48.7% for 1-hydroxypyrene to being 116.1% for 9-hydroxyfluorene of what they were at GF-1A. The kidneys differ in how they process urinary metabolites of PAHs among smokers and nonsmokers.